Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Incyte Corporation (INCY) vs Petróleo Brasileiro SA (PBR) Price & Performance

Incyte CorporationTrade
Petróleo Brasileiro SATrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs Petróleo Brasileiro SA — how do they compare? Incyte Corporation trades at $120.59 (market cap $24.54B), while Petróleo Brasileiro SA trades at $17.92 (market cap $112.19B). The key difference: Petróleo Brasileiro SA is far larger — about 4.6× Incyte Corporation's market cap, and Petróleo Brasileiro SA pays a 9.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

INCYPBR
Market Cap
$24.54B$112.19B
Sector
HealthTechnology
52-Week High
$129.93$22.03
52-Week Low
$81.61$11.54
Enterprise Value
$20.04B$172.61B
Dividend Yield
9.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Incyte Corporation

Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.

Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.

Petróleo Brasileiro SA

PBR trades at $17.91, down 2.29% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a low P/E of 4.53 and robust profitability with a 24.52% net income margin. Recent Q2 2026 earnings beat expectations, with net profit nearly doubling year-over-year, driven by record production and higher oil prices (Reuters, 2026-08-06).

The investment case is supported by attractive valuations and strong cash flows, but faces headwinds from technical selling pressure and regulatory uncertainty. Analyst consensus is bullish with 50% buy ratings, though near-term price action may remain volatile amid broader market conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY

About Petróleo Brasileiro SA

Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.

Read more on PBR